Sickle cell disease (SCD) is a global public health disorder that affects millions of people
across the globe. It is a monogenic disorder caused by an A-to-T point mutation in the β …

As a global health problem, sickle cell anemia affects many world populations. Since its
initial description in the United States almost a century ago, scientists and medical …

Sickle cell disease (SCD) is the most-common monogenic recessive disease in humans,
annually affecting almost 300,000 newborns worldwide, 75% of whom live in Africa …

Abstract Sickle Cell Anemia (SCA) was one of the first hemoglobinopathies to be
discovered. It is distinguished by the mutation-induced expression of a sickle cell variant of …

Since the discovery of sickle cell disease (SCD) in 1910, enormous strides have been made
in the elucidation of the pathogenesis of its protean complications, which has inspired recent …

Although sickle cell anemia was the first molecular disease to be identified, its complex and
fascinating pathophysiology is still not fully understood. A single mutation in the beta-globin …

Sickle cell disease (SCD), the commonest monogenetic disorder worldwide, represents a
major public health burden because of its significant morbidity and mortality. Advances in …

Amilestone was reached in July of this year when Endari, the first new therapeutic for sickle
cell disease in 50 years, was approved by the Food and Drug Administration (FDA). Endari …

The discovery of the molecular basis of sickle cell disease was an important landmark in
molecular medicine. The modern tools of molecular and cellular biology have refined our …

The root cause of sickle cell disease is a single β‐globin gene mutation coding for the sickle
β‐hemoglobin chain. Sickle hemoglobin tetramers polymerize when deoxygenated …